• To evaluate the accuracy and efficacy of the Medtronic REAL-Time continuous glucose monitoring (CGM) glucose sensor in patients with type 1 diabetes.
• Mean absolute relative difference (MARD) and median absolute relative difference (ARD).
• The number and the percentage of glucose sensor readings that fell within ±20% or ±30% of meter reference readings. For glucose readings <80 mg/dL, agreement was assessed within 20 mg/dL.
• The paired glucose sensor-meter readings were plotted on Clarke Error Grid scatter plots. This tool was first used to determine the clinical effectiveness of self-monitoring of blood glucose (SMBG). Today, it is commonly applied to continuous sensor data. The more recently developed Consensus Error Grid was also utilized.
Methods
• A total of 72 subjects with type 1 diabetes wore the glucose sensor continuously in the open-label, multicenter, 6-month study.
• Subjects were between 12 and 80 years of age and wore an insulin pump prior to the start of the study. There were 52 adults (40 ± 11 years) and 20 adolescents (14 ± 1.5 years).
• The CGM system consisted of a glucose sensor, a MiniLink® Transmitter, and a receiver (MiniMed Paradigm® 722 insulin pump).
• Subjects were asked to wear the glucose sensor for 3 consecutive days, and then replace it with a new glucose sensor. Subjects were instructed to wear the glucose sensor for at least 6 days per week during the study.
• The paired glucose sensor and meter values were prospectively obtained during the at-home STAR 1 trial and were analyzed per protocol for accuracy and efficacy.
• Subjects performed SMBG with a meter of choice at least 4 times per day, including glucose sensor calibration.
• Data were uploaded to CareLink™ clinical software via the Internet every 2 weeks during the study.
• Temporally paired glucose measurements from the glucose sensor and the meters were analyzed descriptively and graphically.
• To temporarily pair the glucose sensor and the meter, the MiniMed Paradigm REAL-Time System recorded average glucose sensor values every 5 minutes. Then, the paired points were created by shifting the meter values ahead to the next 5-minute sensor reading. This system reading was used to pair up with the reading for the meter.
Results
• No adverse events occurred that required discontinuation from the study.
• The data set provided 60,050 paired points. Of the study subjects, 85% complied with four fingersticks per day.
There was 89% compliance for glucose sensor usage.
• The mean absolute relative difference (MARD) for overall data was 15.8%, and the median absolute relative difference (ARD) was 10.9%.
• The MARD for adults (47,611 paired points) was 15.2%, and the ARD was 10.5%. The MARD for adolescents (12,439 paired points) was 18.0% and the ARD was 12.4%. 
Conclusions
• This home use study was the biggest of its kind to evaluate sensor accuracy.
• Over the past several years, the performance and reliability of glucose sensors have steadily improved.
• In this study, the MARD was 15.8% and the median ARD was 10.9% versus 19.7% and 15.5%, respectively, for glucose sensor studies completed in 2004. Also, the MARD does not worsen over the prescribed 72 hours of recommended sensor wear.
• The ultimate goal of diabetes management-achieving euglycemic values-depends on the ability to measure glucose in real-time. The establishment of accuracy to the degree demonstrated in this study provides a foundation for this therapy's practical application.
